Vertex Pharmaceuticals's earnings per share without non-recurring items for the
three
months ended in Jun. 2022 was $3.13.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2022 was $12.37.
During the past 12 months, Vertex Pharmaceuticals's average earnings per share (NRI) Growth Rate was 63.20% per year.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 3.70% per year.
During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Vertex Pharmaceuticals's EPS without NRI or its related term are showing as below:
VRTX'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -89.3 Med: -9.3 Max: 114.7
Current: 3.7
During the past 13 years, Vertex Pharmaceuticals's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 114.70% per year. The lowest was -89.30% per year. And the median was -9.30% per year.
VRTX's 3-Year EPS without NRI Growth Rate is ranked worse than 54.56% of 1151
companies
in the Biotechnology industry
Industry Median: 7.50
vs VRTX: 3.70
Vertex Pharmaceuticals's EPS (Diluted) for the
three
months ended in Jun. 2022 was $3.13.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was $12.37.
Vertex Pharmaceuticals's EPS (Basic) for the
three
months ended in Jun. 2022 was $3.17.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2022 was $12.48.
Vertex Pharmaceuticals EPS without NRI Historical Data
The historical data trend for Vertex Pharmaceuticals's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Vertex Pharmaceuticals Annual Data
Trend
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
EPS without NRI
1.04
8.09
4.51
10.29
9.01
Vertex Pharmaceuticals Quarterly Data
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
EPS without NRI
0.26
3.28
3.00
2.96
3.13
Competitive Comparison
For the Biotechnology subindustry, Vertex Pharmaceuticals's EPS without NRI, along with its competitors' market caps and EPS without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vertex Pharmaceuticals EPS without NRI Distribution
For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's EPS without NRI distribution charts can be found below:
* The bar in red indicates where Vertex Pharmaceuticals's EPS without NRI falls into.
Vertex Pharmaceuticals EPS without NRI Calculation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock. In calculating earnings per share without non-recurring items, the dividends of preferred stocks and Non Operating Income need to subtracted from the total net income first.
EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.37
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vertex Pharmaceuticals (NAS:VRTX) EPS without NRI Explanation
A Non Operating Income refers to an entry that appears on a company's financial statements that is unlikely to happen again. It represents a one-time expense involving an unpredictable event and is not part of a firm's normal, day-to-day operations.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Vertex Pharmaceuticals EPS without NRI Related Terms
Thank you for viewing the detailed overview of Vertex Pharmaceuticals's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
3.61(1.22%) Volume: 1,157,343 11:08PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:VRTX has been successfully added to your 
